Archives
-
EZ Cap™ Firefly Luciferase mRNA: Five Questions
2026-10-06
A source-grounded overview of how Cap1 firefly luciferase mRNA functions as a reporter, what its signal can and cannot establish, and how confidently supplier claims and adjacent innate-immunity evidence should be interpreted.
-
Ko 143: BCRP Inhibitor Evidence Guide
2026-10-06
Ko 143 is a selective BCRP inhibitor used to study ABCG2-linked drug efflux and multidrug resistance. Supplier-reported potency and mouse benchmarks support its use as a mechanistic research probe, while a 2026 quercetin study shows that BCRP effects must be separated from metabolism, solubility, and MRP2 activity.
-
AST 487 and KDM4A: Reading MPM Evidence
2026-10-05
AST 487 is examined as a research compound within the emerging KDM4A–mesothelioma framework. This evidence-focused review separates findings from interpretation and explains how the 2021 MPM study informs, but does not by itself validate, compound-specific conclusions.
-
Cytochalasin B in Spiroplasma Cell-Entry Research
2026-10-05
A source-grounded overview of Cytochalasin B (NSC 107658) as an actin-directed research tool, focusing on what a 2019 Drosophila S2-cell study found about Spiroplasma eriocheiris entry, how cytoskeletal inhibitor evidence should be interpreted, and where the findings do not generalize.
-
Peroxynitrite, Calcium Flux, and Cardiac Necroptosis
2026-10-04
Liu et al. identify a mechanistic connection between hyperhomocysteinemia, peroxynitrite, ER-to-mitochondria calcium transfer, and cardiac microvascular endothelial-cell necroptosis during ischemia–reperfusion injury. The study supports IP3R-dependent calcium handling as a candidate therapeutic pathway, while its cell and animal models define important limits on clinical interpretation.
-
EZ Cap™ Firefly Luciferase mRNA as a Delivery Readout
2026-10-03
EZ Cap™ Firefly Luciferase mRNA can function as more than a bioluminescent reporter: it offers a framework for separating payload competence from nanoparticle delivery biology. This article interprets its Cap1 and poly(A) design alongside recent lung-targeting LNP evidence, with emphasis on what luminescence can—and cannot—prove.
-
Molecular Stratification of RNA-Lipid Nanoparticles
2026-10-02
This 2025 Communications Chemistry study introduces cryogenic Orbitrap secondary ion mass spectrometry (Cryo-OrbiSIMS) for label-free molecular depth profiling of RNA-loaded lipid nanoparticles. By combining Cryo-TEM with fragment-specific depth analysis, the authors show that PEG-containing fragments occupy the particle surface while DMG-associated fragments are located deeper near the RNA-rich core, providing direct evidence for lipid stratification and orientation.
-
Ceramides Drive RGNNV Infection Through Autophagy
2026-10-01
A 2026 Journal of Virology study combines global lipidomics with pathway perturbation to show that ceramide accumulation promotes red-spotted grouper nervous necrosis virus replication. The work identifies capsid-protein-associated ceramide remodeling and autophagy as experimentally tractable features of RGNNV infection, while highlighting important limits for translation beyond fish cells.
-
Quercetin-Glycoside LNPs Reduce mRNA Inflammation
2026-10-01
The 2026 Chemical Engineering Journal study developed quercetin-glycoside-incorporated lipid nanoparticles that improved in vivo mRNA delivery while reducing inflammatory responses. Quercetin di-glucoside at a 30 mol% substitution produced a formulation with stronger lymph-node transfection, dendritic-cell activation, and SARS-CoV-2 mRNA-driven adaptive immunity than conventional LNPs.
-
NGFR100W mRNA-LNPs for Peripheral Neuropathy
2026-09-30
The reference study combines codon and signal-peptide engineering with N1-methylpseudouridine-modified mRNA and lipid nanoparticles to produce a less nociceptive NGF variant in vivo. Its results show how transient mRNA expression can support axon growth, reduce pain-related activity, and accelerate recovery of intraepidermal nerve fibers in a paclitaxel-induced neuropathy model.
-
D-Lin-MC3-DMA and Translational mRNA Delivery
2026-09-30
Dlin-MC3-DMA is an ionizable cationic liposome lipid for controlled nucleic-acid delivery. This article connects its formulation logic to a 2025 SDF-1α mRNA peripheral artery disease study and translates the findings into practical assay decisions.
-
Imipramine Workflows for Autophagy Research
2026-09-29
Build a controlled Imipramine workflow that separates transporter potency from cell-state effects in glioma, leukemia, neuronal, and immune models. The framework combines autophagy flux, apoptosis, viability, and lipid measurements so a single endpoint is not mistaken for mechanism.
-
Phenacetin in Human Organoid Pharmacokinetics
2026-09-29
A translational strategy for using Phenacetin as a defined test article in human pluripotent stem cell-derived intestinal organoids, integrating chemical properties, epithelial metabolism, assay design, reproducibility, and responsible interpretation.
-
Imipramine: Autophagy and Apoptosis Workflows
2026-09-28
Imipramine offers a practical pharmacological entry point for connecting autophagy, apoptosis, and cell-state phenotyping. This workflow shows how to evaluate it in glioma and leukemia models while using ceramide-focused virology findings to guide, but not overstate, exploratory antiviral assays.
-
Ceapin-A7 for ATF6α: A Tool for Causal ER-Stress Tests
2026-09-28
Ceapin-A7 is a selective ER stress blocker for isolating ATF6α signaling from broader unfolded protein response effects. This article shows how to use it as a mechanistic probe—and how to interpret it alongside findings from glucocorticoid-induced osteonecrosis research without assuming an unproven pathway connection.